ArticleSmart medicine2022
Co-delivery CPT and PTX prodrug with a photo/thermo-responsive nanoplatform for triple-negative breast cancer therapy.
Article in Smart medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Research trends on nanomaterials in triple negative breast cancer (TNBC): a bibliometric analysis from 2010 to 2024.Drug delivery and translational research · 2026Article
- Synergistic effect of pH-sensitive PEGylated RG3-chitosan prodrug nanoparticles encapsulated celastrol on pancreatic cancer.Drug delivery · 2025Article
- Cryotherapy and thermotherapy in the management of osteoarthritis and rheumatoid arthritis: A comprehensive review.Fundamental research · 2025Review
- Arachidonic acid in aging: New roles for old players.Journal of advanced research · 2025Review
- MSAB limits osteoarthritis development and progression through inhibition of β-catenin-DDR2 signaling.Bioactive materials · 2025Article
- Recent development of micro-nano carriers for oral antineoplastic drug delivery.Materials today. Bio · 2025Review
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
- Photothermally Driven Ultrafast Polymerase Chain Reaction: Mechanisms, Nanomaterial Architectures, and System Integration.Research (Washington, D.C.) · 2025Review
- Intelligent bacteria-targeting ZIF-8 composite for fluorescence imaging-guided photodynamic therapy of drug-resistant superbug infections and burn wound healing.Exploration (Beijing, China) · 2024Article
- Integrated photothermal microcarriers for precise exosome-secreted microRNA profiling in breast cancer diagnosis.Quantitative biology (Beijing, China) · 2024Article
- Photothermal responsive porous hollow microneedles as Chinese medicine versatile delivery system for wound healing.Smart medicine · 2024Article
- Exploiting the Warburg Effect: Co-Delivery of Metformin and FOXK2 siRNA for Ovarian Cancer Therapy.Small science · 2024Article
- Thyroid Cancer Central Lymph Node Metastasis Risk Stratification Based on Homogeneous Positioning Deep Learning.Research (Washington, D.C.) · 2024Article
- Remote actuation and on-demand activation of biomaterials pre-incorporated with physical cues for bone repair.Theranostics · 2024Review
- Ultrasound-Responsive Oxygen-Carrying Pollen for Enhancing Chemo-Sonodynamic Therapy of Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma.Materials today. Bio · 2023Article
- Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy.Nano-micro letters · 2023Review
- Designing Bioorthogonal Reactions for Biomedical Applications.Research (Washington, D.C.) · 2023Review
- NIR-responsive carrier-free nanoparticles based on berberine hydrochloride and indocyanine green for synergistic antibacterial therapy and promoting infected wound healing.Regenerative biomaterials · 2023Article
- Co-delivery CPT and PTX prodrug with a photo/thermo-responsive nanoplatform for triple-negative breast cancer therapy.Smart medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is still the most aggressive cancer in women. Combination chemotherapy holds great potential for cancer therapy; however, the off-target and side effects of free chemotherapy administration remain a major challenge. In this study, we developed a photo/thermo-responsive nanoplatform that can be used for TNBC treatment via photothermic therapy in combination with multidrug therapy. By conjugating the chemotherapy drug PTX prodrug on the surface of mesoporous silica-coated gold nanorod nanoparticles and then loading another chemotherapy drug, CPT, the Au@MSN-PTX@CPT nanoparticles exhibited great photothermal response, redox response drug release and cancer cell inhibition abilities. Otherwise, we further coated the Au@MSN-PTX@CPT nanoparticle with a temperature-sensitive polymer poly(N-isopropylacrylamide-co-methacrylic acid) (p(NIPAM-co-MAAc)), and the polymer-coated Au@MSN-PTX@TPT@polymer nanoparticles showed perfect near-infrared (NIR) light controlled drug release. Finally, the Au@MSN-PTX@CPT@polymer nanoparticles were injected into the 4T1 breast cancer mouse model. The Au@MSN-PTX@CPT@polymer nanoparticles preferably accumulated at the tumor site and had reduced chemotherapy injuries and great antitumor activity when combined with 650 nm laser treatment. In summary, our developed Au@MSN-PTX@CPT@polymer nanoparticles served as a good method for controlled chemodrug delivery and provided a good choice for TNBC combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.